Dihydropyridine neuropeptide Y Y(1) receptor antagonists

  • Bioorg Med Chem Lett. 2002 Feb 11;12(3):379-82. doi: 10.1016/s0960-894x(01)00761-2.
Graham S Poindexter  1 ,  Marc A Bruce ,  Karen L LeBoulluec ,  Ivo Monkovic ,  Scott W Martin ,  Eric M Parker ,  Larry G Iben ,  Rachel T McGovern ,  Astrid A Ortiz ,  Jennifer A Stanley ,  Gail K Mattson ,  Michael Kozlowski ,  Meredith Arcuri ,  Ildiko Antal-Zimanyi
Affiliations
  • 1. Pharmaceutical Research Institute, Bristol-Myers Squibb Co., 5 Research Parkway, 06492-7660, Wallingford, CT 06492-7660, USA. [email protected]
PMID: 11814801 DOI: 10.1016/s0960-894x(01)00761-2
Abstract

Dihydropyridine 5a was found to be an inhibitor of neuropeptide Y(1) binding in a high throughput (125)I-PYY screening assay. Structure-activity studies around certain portions of the dihydropyridine chemotype identified BMS-193885 (6e) as a potent and selective Y(1) receptor antagonist. In a forskolin-stimulated c-AMP production assay using CHO cells expressing the human Y(1) receptor, 6e demonstrated full functional antagonism (K(b)=4.5 nM). Compound 6e inhibited NPY-induced feeding in satiated rats when dosed at 3.0 and 10.0 mg/kg (IP), and also decreased spontaneous overnight food consumption in rats at doses of 10 and 20 mg/kg (IP).

Products